iMDx Appoints New Vice President of Marketing
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) has announced a significant addition to its executive team with the appointment of Steven Tahmooressi as Vice President of Marketing. This move comes as the company gears up for the launch of its clinical kitted assay, GraftAssureDx, expected to hit the market in the near future.
Elevating Marketing Initiatives
Steven Tahmooressi is stepping into this critical role, bringing along an impressive 25 years of experience in the healthcare industry, particularly in transplantation, oncology, and immunology. His expertise will drive the global marketing efforts of the GraftAssure family of assays and future products, potentially marking a pivotal moment for iMDx.
Professional Background
Prior to joining iMDx, Mr. Tahmooressi served as the Global Brand Lead of Established Products Marketing at Astellas Pharma, where he oversaw various transplant, urology, and oncology brands. His career includes important positions at leading firms such as Abbott Laboratories and Bristol-Myers Squibb, where he excelled in diverse marketing roles.
Mission-Critical Product Launch
“Our focus on developing a robust product for transplant rejection testing has been unwavering,” said iMDx CEO Josh Riggs. “As we prepare for the FDA authorization of GraftAssureDx, Steven’s appointment is strategic in driving our market presence, especially in high-demand regions including the U.S., Europe, Japan, the Middle East, and Asia Pacific.”
Since beginning his tenure with the company last September, Tahmooressi has already made a significant impact. He has engaged with customers and actively participated in industry events such as the annual meeting of the American Society of Histocompatibility & Immunogenetics, showcasing iMDx's commitment to its stakeholders.
Transforming Transplant Diagnostics
At the heart of iMDx's mission is the goal to democratize access to molecular diagnostic testing. Their flagship product, the GraftAssure family of assays, aims to facilitate improved testing for transplant rejection. This family includes GraftAssureCore, which is currently reimbursed by Medicare and performed in their CLIA-certified lab.
Innovative Technology and Market Potential
The GraftAssure product line represents a significant innovation in transplant diagnostics. The upcoming GraftAssureDx kit, designed for hospitals, intends to enhance accessibility for kidney transplant patients significantly. The market potential is substantial, with an estimated addressable market exceeding $1 billion for kitted transplant rejection testing.
Utilizing an established biomarker known as donor-derived cell-free DNA (dd-cfDNA), these assays provide insights into transplant rejection, a crucial area in patient care. “I am dedicated to expanding access to necessary tools for healthcare providers and their patients,” says Tahmooressi. “The collaboration with transplant specialists has revealed the transformative potential that our products could bring.”
GraftAssure Product Overview
The company’s ongoing efforts aim to commercialize techniques developed by its scientists both in the United States and Germany over the last decade, which established dd-cfDNA as a credible marker for transplant rejection. The GraftAssure brand offers several products, including:
- GraftAssureCore – A laboratory-developed test (LDT) currently reimbursed by Medicare and provided at iMDx's Nashville lab, which has been rebranded from VitaGraft.
- GraftAssureIQ – A research-use-only (RUO) kit designed for non-clinical applications.
- GraftAssureDx – An upcoming diagnostic kit aimed to aid clinical decision-making, with plans for FDA submission.
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc., or iMDx, is a cutting-edge company focusing on precision diagnostics with the goal of improving patient outcomes through accessible molecular diagnostics. The company relocated its headquarters to Nashville, TN, creating a central hub for innovation. With ongoing advancement in research and product development, iMDx is committed to enhancing healthcare through meaningful diagnostic solutions.
Frequently Asked Questions
What is the role of Steven Tahmooressi at iMDx?
Steven Tahmooressi is appointed as the Vice President of Marketing, responsible for leading the marketing efforts for the GraftAssure family of assays.
What products are part of the GraftAssure family?
The GraftAssure family includes GraftAssureCore, GraftAssureIQ, and the upcoming GraftAssureDx, all aimed at improving transplant diagnostics.
How does the GraftAssure assay improve transplantation?
These assays quantify donor-derived cell-free DNA, providing insights into transplant rejection and facilitating timely medical decisions.
What is the market potential for GraftAssure products?
The estimated addressable market for kitted transplant rejection testing exceeds $1 billion, offering significant opportunities for iMDx to impact patient care.
Where can investors find more information about iMDx?
Investors can learn more about Insight Molecular Diagnostics and its offerings by visiting their official investor relations website.
